Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as surinabant (SR147778)
surinabant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | surinabant 2,5 mg/day |
| 3 | ACTIVE_COMPARATOR | surinabant 5 mg/day |
| 4 | ACTIVE_COMPARATOR | surinabant 10 mg/day |
| Name | Type | Description |
|---|---|---|
| surinabant (SR147778) | DRUG | oral administration |
| placebo | DRUG | oral administration |
Inclusion Criteria: * Patients over legal age smoking at least 10 cigarettes/day as a mean within the 6 months preceding the screening visit. Exclusion Criteria: * Patients with a limited level of motivation. * Other participant in a household enrolled in the study. * Patients who have smoked or ...
Surinabant is an investigational small molecule developed by Sanofi for smoking cessation. It was studied as an aid to help people stop smoking and reached Phase 2 clinical development. It is not an approved medicine; its only recorded trial has completed, and no active trials are ongoing.
Surinabant was developed as an aid to smoking cessation, meaning it was tested to help adults quit smoking. The Phase 2 SURSMOKE trial enrolled 810 participants aged 18 and older across eight European countries. The program is not currently active, and surinabant is not an approved treatment for smoking cessation.
Surinabant targets CNR1, the cannabinoid receptor type 1, and acts as an antagonist at that receptor. By blocking CNR1 signaling, it was designed to reduce the rewarding effects associated with smoking. This mechanism was the basis for its evaluation as a smoking cessation aid in Phase 2 testing.
Surinabant was developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 2 SURSMOKE trial that evaluated the drug as an aid to smoking cessation. The compound is also referenced in chemical databases under the identifier CHEMBL189676.
Surinabant reached Phase 2 clinical development. Its single recorded trial, SURSMOKE, has completed, and no active trials are ongoing. Surinabant is not FDA approved and remains an investigational agent rather than a marketed product.
Surinabant was studied in one clinical trial, NCT00432575, titled Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE). The Phase 2 trial was randomized, double blind, and placebo controlled, enrolling 810 participants across Belgium, France, Germany, Italy, Norway, Spain, Sweden, and Switzerland. It has completed.
Yes, surinabant is also known as SR147778. Both names refer to the same Sanofi compound, a CNR1 antagonist that was tested in Phase 2 as an aid to smoking cessation. Searches for either name point to the same investigational drug and the same completed SURSMOKE trial.